Who Generates Higher Gross Profit? Dr. Reddy's Laboratories Limited or Halozyme Therapeutics, Inc.

Dr. Reddy's vs. Halozyme: A Profitability Showdown

__timestampDr. Reddy's Laboratories LimitedHalozyme Therapeutics, Inc.
Wednesday, January 1, 20147580100000052602000
Thursday, January 1, 201585403000000105812000
Friday, January 1, 201692281000000113485000
Sunday, January 1, 201778356000000285461000
Monday, January 1, 201876304000000141726000
Tuesday, January 1, 201983430000000150446000
Wednesday, January 1, 202094009000000224227000
Friday, January 1, 2021103077000000361897000
Saturday, January 1, 2022113840000000520812000
Sunday, January 1, 2023202972000000636892000
Monday, January 1, 2024163607000000855907000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Gross Profit Analysis

In the competitive world of pharmaceuticals and biotechnology, understanding who leads in profitability can offer valuable insights. Dr. Reddy's Laboratories Limited, a major player in the pharmaceutical industry, has consistently outperformed Halozyme Therapeutics, Inc. in terms of gross profit from 2014 to 2023. Over this period, Dr. Reddy's Laboratories saw a remarkable increase in gross profit, peaking in 2023 with a staggering 167% growth compared to 2014. In contrast, Halozyme Therapeutics, while showing growth, achieved a more modest increase of approximately 1,110% over the same period. This stark difference highlights Dr. Reddy's Laboratories' robust market position and strategic prowess. However, it's important to note that data for 2024 is incomplete, leaving room for future developments. As the industry evolves, these insights provide a snapshot of the financial health and strategic direction of these two companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025